ACUR · As filed with the SEC
Acura Pharmaceuticals cash flow statement, by fiscal year
The statement as Acura Pharmaceuticals presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
CONSOLIDATED STATEMENTS OF CASH FLOWS · USD
| USD | FY2021 Year ended Dec 31, 2021 | FY2020 Year ended Dec 31, 2020 | FY2019 Year ended Dec 31, 2019 | FY2018 Year ended Dec 31, 2018 |
|---|---|---|---|---|
| Cash Flows from Operating Activities: | ||||
| Net loss | — | (1,208,000) | (3,774,000) | (3,842,000) |
| Net loss | (879,000) | — | — | — |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||
| Depreciation | 47,000 | 56,000 | 66,000 | 73,000 |
| Provision for sales returns | — | — | — | 0 |
| Non-cash stock-based compensation | 58,000 | 36,000 | 108,000 | 218,000 |
| Capitalized debt discount | — | — | (13,000) | (172,000) |
| Amortization of debt discount and deferred debt issue costs | — | — | 66,000 | 87,000 |
| Amortization of intangible asset | 26,000 | 69,000 | 207,000 | 207,000 |
| Loss on debt extinguishment | — | — | 2,600,000 | (296,000) |
| Amortization of right of use asset | 17,000 | — | — | — |
| Impairment charge on intangible asset | 47,000 | 668,000 | — | — |
| Loss on disposal of equipment | — | — | 1,000 | 0 |
| Sales return liability | 0 | (223,000) | — | (31,000) |
| Gains on forgiveness of loans under CARES Act | (535,000) | — | — | — |
| Changes in assets and liabilities: | ||||
| Trade accounts receivable | — | — | — | 0 |
| Royalty receivable | 0 | 52,000 | 55,000 | (66,000) |
| Inventories | — | — | — | 0 |
| Collaboration revenue receivable from related party | 119,000 | (119,000) | (78,000) | 0 |
| License fee receivable from related party | 350,000 | (400,000) | — | — |
| Prepaid expenses and other current assets | (10,000) | (17,000) | 44,000 | 109,000 |
| Income taxes refundable | — | 68,000 | — | — |
| Income taxes refundable | 0 | — | 67,000 | 0 |
| Accounts payable | 161,000 | (206,000) | (368,000) | 602,000 |
| Accrued expenses | (394,000) | 46,000 | (11,000) | (343,000) |
| Accrued interest on loan | — | — | — | (566,000) |
| Accrued interest on related party loans | 199,000 | 449,000 | 394,000 | 110,000 |
| Other current liabilities | 52,000 | 10,000 | 18,000 | 2,000 |
| Net cash used in operating activities | (742,000) | (719,000) | (618,000) | (3,908,000) |
| Proceeds from transfer of equipment to licensee | — | — | — | 0 |
| Proceeds from transfer of inventory to licensee | — | — | — | 0 |
| Net cash provided by investing activities | — | — | — | 0 |
| Cash Flows from Financing Activities: | ||||
| Proceeds from distribution of RSU awards | 3,000 | 3,000 | 14,000 | 2,000 |
| Statutory minimum payroll withholding taxes paid on the distribution of shares pursuant to RSU awards | (8,000) | (2,000) | — | — |
| Proceeds from loan under CARES Act | 266,000 | 269,000 | — | — |
| Proceeds from issuance of promissory note to related party | 150,000 | — | 1,375,000 | 4,350,000 |
| Principal payments loan | — | — | — | (2,573,000) |
| Issuance of common stock | — | — | — | 0 |
| Payments on finance lease | (17,000) | — | — | — |
| Net cash provided by financing activities | 394,000 | 270,000 | 1,389,000 | 1,779,000 |
| Net decrease in cash | (348,000) | (449,000) | 771,000 | (2,129,000) |
| Cash at beginning of period | 413,000 | 862,000 | 91,000 | 2,220,000 |
| Cash at end of end of period | 65,000 | 413,000 | 862,000 | 91,000 |
| Supplemental Disclosures of Cash Flow Information: | ||||
| Cash interest payments on loans | 0 | — | — | 759,000 |
| Cash paid for income taxes | 0 | — | — | — |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.